Comparative Pharmacology
Head-to-head clinical analysis: ENDURON versus HYDRO D.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURON versus HYDRO D.
ENDURON vs HYDRO-D
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, reducing sodium and chloride reabsorption and increasing water excretion.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Oral, 2.5–5 mg once daily. Maximum dose 10 mg/day.
25-100 mg orally once daily in the morning.
None Documented
None Documented
Terminal elimination half-life: 24-48 hours (mean 36 hours); prolonged in renal impairment or heart failure, allowing once-daily dosing.
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Primarily renal (approximately 50-70% as unchanged drug); biliary/fecal (15-30%); dose adjustment required in renal impairment (CrCl <30 mL/min).
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic